Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levothyroxine supplementation for NTIS in critically ill ICU patients
ChiCTR2600132530Phase 4Not yet recruiting
- Sponsor
- Subei People's Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levothyroxine sodium in euthyroid sick syndrome (NTIS) (2 arms), sponsored by Subei People's Hospital. Primary endpoint: 28-day survival rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
levothyroxine sodium
03
Conditions
euthyroid sick syndrome (NTIS)
Beyond the preview
Go deeper on ChiCTR2600132530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132530.